SCHEMBL13087006

SCHEMBL13087006

CC(N)(Cc1cc(O)c(O)cc1[18F])C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.57
HSD17B10 Q99714 5/20 0.57
BLM P54132 4/20 0.57
KDM4E B2RXH2 4/20 0.57
MAPT P10636 4/20 0.57
ALOX15 P16050 4/20 0.57
MEN1 O00255 4/20 0.57
RECQL P46063 4/20 0.57
KMT2A Q03164 4/20 0.57
CYP3A4 P08684 4/20 0.57
ALDH1A1 P00352 3/20 0.57
POLB P06746 3/20 0.57
HPGD P15428 3/20 0.57
USP2 O75604 3/20 0.57
APEX1 P27695 3/20 0.57
CYP1A2 P05177 2/20 0.57
PMP22 Q01453 2/20 0.57
ADRA1A P35348 2/20 0.57
EGFR P00533 1/20 0.57
FYN P06241 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13086848 1.00 TDP1 (0.57) TDP1HSD17B10BLMKDM4EMAPT
SCHEMBL11398572 1.00 TDP1 (0.57) TDP1HSD17B10BLMKDM4EMAPT
SCHEMBL11394224 1.00 TDP1 (0.57) TDP1HSD17B10BLMKDM4EMAPT
Hydrochloric Acid SCHEMBL11394769 0.98 TDP1 (0.55) TDP1HSD17B10BLMKDM4EMAPT
Methoxymethane SCHEMBL11400056 0.95 TDP1 (0.53) TDP1HSD17B10BLMKDM4EMAPT
SCHEMBL11442423 0.94 TDP1 (0.51) TDP1HSD17B10BLMKDM4EMAPT
SCHEMBL12679277 0.82 BLM (0.57) TDP1HSD17B10BLMKDM4EMAPT
SCHEMBL13086896 0.82 BLM (0.57) TDP1HSD17B10BLMKDM4EMAPT
SCHEMBL13086903 0.82 BLM (0.57) TDP1HSD17B10BLMKDM4EMAPT
SCHEMBL6719985 0.81 KDM4E (0.48) TDP1HSD17B10BLMKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130060063-A1 METHOD FOR PRODUCING PRECURSORS FOR L-3,4-DIHYDROXY-6-[18F]FLUOROPHENYLALANINE AND 2-[18F]FLUORO-L-TYROSINE AND THE A-METHYLATED DERIVATIVES THEREOF, PRECURSOR, AND METHOD FOR PRODUCING L-3,4DIHYDROXY-6-[18F]FLUOROPHENYLALANINE AND 2-[18F]FLUORO-L-TYROSINE AND THE A-METHYLATED DERIVATIVES FROM THE PRECURSOR WAGNER FRANZISKA (DE) 2013-03-07 US disclosed
US-20100261913-A1 METHOD FOR PRODUCING PRECURSORS FOR L-3,4-DIHYDROXY-6- [18F] FLUOROPHENYL ALAINE AND 2- [18F] FLUORO-L-TYROSINE AND THE ALPHA-METHYLATED DERIVATIVES THEREOF, PRECURSOR, AND METHOD FOR PRODUCING L-3, 4DIHYDROXY-6- [18F] FLUOROPHENYLALANINE AND 2- [18F] FLUORO-L-TYROSINE AND THE ALPHA-METHYLATED DERIVATIVES FROM THE PRECURSOR FORSCHUNGSZENTRUM JUELICH GMBH (DE) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261913-A1 METHOD FOR PRODUCING PRECURSORS FOR L-3,4-DIHYDROXY-6- [18F] FLUOROPHENYL ALAINE AND 2- [18F] FLUORO-L-TYROSINE AND THE ALPHA-METHYLATED DERIVATIVES THEREOF, PRECURSOR, AND METHOD FOR PRODUCING L-3, 4DIHYDROXY-6- [18F] FLUOROPHENYLALANINE AND 2- [18F] FLUORO-L-TYROSINE AND THE ALPHA-METHYLATED DERIVATIVES FROM THE PRECURSOR TH, DAO, FTO TDP1 940/4885HSD17B10 1117/4885BLM 3747/4885
US-20130060063-A1 METHOD FOR PRODUCING PRECURSORS FOR L-3,4-DIHYDROXY-6-[18F]FLUOROPHENYLALANINE AND 2-[18F]FLUORO-L-TYROSINE AND THE A-METHYLATED DERIVATIVES THEREOF, PRECURSOR, AND METHOD FOR PRODUCING L-3,4DIHYDROXY-6-[18F]FLUOROPHENYLALANINE AND 2-[18F]FLUORO-L-TYROSINE AND THE A-METHYLATED DERIVATIVES FROM THE PRECURSOR TH, FTO, PAH TDP1 1238/4885HSD17B10 1116/4885BLM 4400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.